Gustavo Bretas, MD
@golbretas.bsky.social
Medical oncologist from Rio de Janeiro, Brazil.
🌍 EUROPA Trial Highlights: In women 70+ with ER+ EBC, RT preserves HRQOL better than ET at 24 months, with fewer side effects. Both RT and ET are viable single-modality options for tailored care. 🤝 #SABCS24 #BreastCancer Well done, @icromeattini.bsky.social @oncoalert.bsky.social @sabcs.bsky.social
December 12, 2024 at 3:54 PM
🌍 EUROPA Trial Highlights: In women 70+ with ER+ EBC, RT preserves HRQOL better than ET at 24 months, with fewer side effects. Both RT and ET are viable single-modality options for tailored care. 🤝 #SABCS24 #BreastCancer Well done, @icromeattini.bsky.social @oncoalert.bsky.social @sabcs.bsky.social